Oncology

Latest News

NSCLC | Image: Lung Cancer Foundation of America
Zongertinib Shows Durable Responses With No Interstitial Lung Disease in HER2-Mutated Advanced NSCLC

April 28th 2025

Results could give patients with HER2-mutated non–small cell lung cancer (NSCLC) an oral therapy option.

Considering the life-threatening risk of TLS, the researchers underscored the importance of identifying patients at particular risk of the complication. | Image credit: mi_viri - stock.adobe.com
Optimized Strategies Needed for TLS Prevention, Intervention in SCLC

April 23rd 2025

Diabetes monitoring | Image credit: abidika - stock.adobe.com
New-Onset Type 2 Diabetes Linked to Higher Cancer Risk

April 23rd 2025

Vitamin D | Image credit: Galina Zhigalova - stock.adobe.com
Vitamin D’s Potential Role in Colorectal Cancer Prevention, Immune Health

April 23rd 2025

The study highlighted symptom patterns in the short-term preceding ED visits and unplanned hospitalizations using a previously validated natural language processing a pipeline. | Image credit: Tyler Olson - stock.adobe.com
Symptom Documentation Differences in Acute Cancer Care Suggest Sociodemographic Disparities

April 22nd 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

This Week in Managed Care: December 2, 2016
December 2nd 2016

This Week in Managed Care: December 2, 2016

This week, the top stories in managed care included the president-elect's picks for HHS and CMS, the American Diabetes Association addressed psychosocial care for patients with diabetes, and the American Society of Clinical Oncology released criteria on creating clinical pathways.
Site Logo
December 1st 2016

Precision CAR-T Trial Shows Early Signs of Success in Multiple Myeloma

Surabhi Dangi-Garimella, PhD
Interim data analysis of a phase 1 trial of chimeric antigen receptor-T cells (CAR-T) targeting the B-cell maturation antigen in heavily pretreated patients with multiple myeloma has identified an objective anti-tumor response, with limited toxicity.
Site Logo
November 30th 2016

Statins Could Reduce Mortality in Patients With Multiple Myeloma

Surabhi Dangi-Garimella, PhD
Statin use was associated with a reduction in all-cause and multiple myeloma-specific mortality.
Site Logo
November 30th 2016

House Committee to Scrutinize the Working of USPSTF

Surabhi Dangi-Garimella, PhD
The House Energy and Commerce Committee's subcommittee on health will gather testimonial from leaders of the US Preventive Services Task Force, the American Academy of Family Physicians, and the American Urologic Association, on a bill called H.R. 1151.
Dr Leonard Fromer Discusses Precision Medicine in Oncology
November 30th 2016

Dr Leonard Fromer Discusses Precision Medicine in Oncology

Cancer patients can now receive individually personalized treatment thanks to algorithms that account for their own unique factors, according to Leonard M. Fromer, MD, FAAFP, executive medical director of the Group Practice Forum.
Site Logo
November 29th 2016

Hospitalization a Major Burden on Medicare Beneficiaries With Cancer

Surabhi Dangi-Garimella, PhD
A nationally representative study among patients enrolled in Medicare, who were diagnosed with cancer, found that out-of-pocket costs averaged at 23.7% of their household income. A majority of these costs could be attributed to hospitalization.
Site Logo
November 29th 2016

ASCO Framework Can Help Providers Assess Clinical Pathway Programs

Surabhi Dangi-Garimella, PhD
The American Society of Clinical Oncology (ASCO) has released the Criteria for High-Quality Clinical Pathways in Oncology, which is expected to help providers assess the quality, utility, and integrity of pathway programs in the United States.
Site Logo
November 29th 2016

What We're Reading: Warren Says Pharma "Hijacked" Cures Bill

AJMC Staff
What we're reading, November 29, 2016: Warren cries foul over pharma's role in legislation; women fear what will happen to coverage under Trump; and Gallup poll finds most Americans want changes or repeal of the Affordable Care Act.
Site Logo
November 28th 2016

21st Century Cures Set for a Midweek House Vote

Surabhi Dangi-Garimella, PhD
With $372 million carved out for the National Institutes of Health innovation account in 2017, and about $114 million assigned to President Barack Obama’s Precision Medicine Initiative for the fiscal year 2018, the 21st Century Cures Act has a lot at stake for healthcare in the United States.
Kim Eason Explains Horizon's Use of Bundled Payment Model for Oncology
November 26th 2016

Kim Eason Explains Horizon's Use of Bundled Payment Model for Oncology

Oncology is a perfect fit for the bundled payment model, because it evaluates the outcomes, patient satisfaction, and cost of an oncology episode, said Kim Eason, manager at Horizon Blue Cross Blue Shield of NJ. She said that Horizon adopted the bundled payment model early to cope with New Jersey’s rising healthcare costs.
Site Logo
November 26th 2016

Mitigating Chemotherapy-Induced Neutropenia With a Novel Same-Day Treatment

AJMC Staff
Trial data on the use of plinabulin for mitigating chemotherapy-induced neutropenia with docetaxel will be presented as a poster at the American Society of Hematology’s annual meeting in San Diego.
Site Logo
November 25th 2016

Risk Factors for Neutropenia and Infections in Childhood ALL

AJMC Staff
A study published in the Annals of Oncology has analyzed data on young patients with acute lymphoblastic leukemia (ALL) to evaluate risk factors for febrile neutropenia and infection-related complications.
The Future of Value-Based Care and Payment Models in Cancer Care
November 24th 2016

The Future of Value-Based Care and Payment Models in Cancer Care

Do APMs Incorporate Survivorship Care in Oncology?
November 24th 2016

Do APMs Incorporate Survivorship Care in Oncology?

Patient Centricity of Care Delivery and Payment Models
November 24th 2016

Patient Centricity of Care Delivery and Payment Models

The Balancing Act of Healthcare Costs
November 24th 2016

The Balancing Act of Healthcare Costs

Innovative Technology and Healthcare Costs
November 24th 2016

Innovative Technology and Healthcare Costs

Importance of Data Sharing in Healthcare
November 24th 2016

Importance of Data Sharing in Healthcare

Leveraging Health IT in Cancer Care
November 24th 2016

Leveraging Health IT in Cancer Care

Who Shares the Maximum Risk With Innovative Treatments in Oncology?
November 24th 2016

Who Shares the Maximum Risk With Innovative Treatments in Oncology?

Site of Service and the Challenge of Value-Based Care
November 24th 2016

Site of Service and the Challenge of Value-Based Care

Risk-Based Contracting in Oncology
November 24th 2016

Risk-Based Contracting in Oncology

Benefits of a Medical Home Model in Oncology
November 24th 2016

Benefits of a Medical Home Model in Oncology

Population Health and APMs
November 24th 2016

Population Health and APMs

Is the Oncology Care Model Patient Centered?
November 24th 2016

Is the Oncology Care Model Patient Centered?

Value-Based Care and APMs in Oncology: A Payer Perspective
November 24th 2016

Value-Based Care and APMs in Oncology: A Payer Perspective

Adapting and Paying for Value-Based Care
November 24th 2016

Adapting and Paying for Value-Based Care

Defining Alternative Payment Models
November 24th 2016

Defining Alternative Payment Models

Site Logo
November 23rd 2016

Another Death Reported in Juno's CAR-T Trial in Patients With ALL

AJMC Staff
Within 4 months of the last reported incident, Juno Therapeutics has again halted the phase 2 “Rocket” trial of JCAR015 in patients with relapsed or refractory B cell acute lymphoblastic leukemia (ALL).
Site Logo
November 23rd 2016

5 Key Highlights From the Patient-Centered Oncology Care Meeting

Surabhi Dangi-Garimella, PhD
Here's a glimpse into what The American Journal of Managed Care’s 5th annual Patient-Centered Oncology Care® meeting had in store for its attendees.
<1
...
858687888990919293
...
184>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo